A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania

被引:14
|
作者
Perrin, E.
Anand, E. [1 ]
Dyachkova, Y.
Wagner, T. [2 ]
Frediani, S. [3 ]
Ballerini, A. [4 ]
机构
[1] Lilly Neurosci Res Ctr, Windlesham GU20 6PH, Surrey, England
[2] Lilly Deutschland GmbH, D-61350 Bad Homburg, Germany
[3] Psychiat Dept Venice, Natl Mental Hlth Serv, Venice, Italy
[4] Santa Maria Nuova Hosp, Serv Psichiatr Diagnosi & Cura, Florence, Italy
关键词
Agitation; Schizophrenia; Bipolar mania; IM psychotropic drugs; Acute dystonia; Akathisia; Parkinsonism; OLANZAPINE; MANAGEMENT; ANTIPSYCHOTICS; EFFICACY;
D O I
10.1016/j.eurpsy.2010.04.005
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
This naturalistic, observational pan-European study assessed the safety and early effectiveness of intramuscular (IM) psychotropic treatments in patients with acute agitation suffering from schizophrenia or bipolar mania. One thousand nine hundred and forty of 1945 patients completed the 24-hour observation period after initial IM treatment. Patients from 12 European countries were included (mean age 39 years; 58% male, 66% schizophrenia). IM treatment was at the physician's discretion. The primary objective was to describe the acute tolerability of IM psychotropic therapies in clinical practice, with particular emphasis on EPS. At baseline, 68% of the patients received IM monotherapy, with IM olanzapine most commonly prescribed (36%). During the first 24 hours, 190 (9.8%) patients experienced EPS. The occurrence of EPS was statistically significantly lower in patients treated with IM olanzapine compared to those treated with other IM psychotropic medications (mainly typical antipsychotics and benzodiazepines): acute dystonia: 1.1%, 95% CI 0.5-2.3 and 2.9%, CI 2.0-4.0; akathisia: 2.3%, CI 1.3-3.7 and 5.5%, CI 4.3-6.9; Parkinsonism: 2.9%, CI 1.8-4.4 and 7.8%, CI 6.4-9.4, respectively. Anticholinergic treatment was given to 12% IM olanzapine versus 31% non-olanzapine treated patients. Acute agitation after 24 hours was reduced by 1.68 (95% CI 1.46-1.91) points on the Clinical Global Impression of Severity (CGI-S) in IM olanzapine patients and 1.51 (95% CI 1.30-1.73) points in non-olanzapine patients. Additional psychotropic medication was required for 90% of the patients during the first 24 hours of treatment. Results provide naturalistic evidence for low EPS rates and improvement of agitation with IM psychotropic medications during acute states of patients suffering from acute mania or schizophrenia. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:234 / 239
页数:6
相关论文
共 50 条
  • [31] Effectiveness of electroconvulsive therapy in patients with treatment resistant schizophrenia: A retrospective study
    Grover, Sandeep
    Chakrabarti, Subho
    Hazari, Nandita
    Avasthi, Ajit
    PSYCHIATRY RESEARCH, 2017, 249 : 349 - 353
  • [32] Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics
    Dikeos, Dimitris
    Badr, Mohamed Gamal
    Yang, Fude
    Pesek, Marjeta Blinc
    Fabian, Zsolt
    Tapia-Paniagua, Guillermo
    Hudita, Cristina
    Okasha, Tarek
    D'yachkova, Yulia
    Harrison, Gavan
    Treuer, Tamas
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2010, 11 (04) : 667 - 676
  • [33] Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial
    Kudla, Duerten
    Lambert, Martin
    Domin, Sabine
    Kasper, Siegfried
    Naber, Dieter
    EUROPEAN PSYCHIATRY, 2007, 22 (03) : 195 - 202
  • [34] Effectiveness of antipsychotics for managing agitated delirium in patients with advanced cancer: a secondary analysis of a multicenter prospective observational study in Japan (Phase-R)
    Ken Kurisu
    Shuji Inada
    Isseki Maeda
    Hiroyuki Nobata
    Asao Ogawa
    Satoru Iwase
    Megumi Uchida
    Tatsuo Akechi
    Koji Amano
    Nobuhisa Nakajima
    Tatsuya Morita
    Masahiko Sumitani
    Kazuhiro Yoshiuchi
    Supportive Care in Cancer, 2024, 32
  • [35] Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia
    Karagianis, Jamie
    Williams, Richard
    Davis, Lori
    Procyshyn, Ric
    Monga, Neerav
    Hanley, James
    Chandrasena, Ranjith
    Thakur, Aruna
    Dickson, Ruth
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (09) : 2121 - 2132
  • [36] A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia
    Arango, C.
    Gomez-Beneyto, M.
    Brenlla, J.
    Gasto, C.
    Sarramea-Crespo, F.
    Chamorro, L.
    Masramon, X.
    Diez, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 (6-7) : 456 - 463
  • [37] Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study
    Li, Li
    Zhang, Ruiqin
    Zeng, Jing
    Ke, Hu
    Peng, Xiuhong
    Huang, Liying
    Zhang, Hongmei
    Chen, Zhijing
    Li, Tian Tian
    Tan, Qiuxiao
    Yang, Ying
    Li, Xiaofang
    Li, Xin
    BMC WOMENS HEALTH, 2020, 20 (01)
  • [38] The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
    Liang, Ying
    Yu, Xin
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 1163 - 1173
  • [39] The efficacy and safety of cariprazine in schizophrenia patients with insufficient effectiveness of previous antipsychotic therapy: a latvian observational study
    Rancans, E.
    Barabassy, A.
    Sebe, B.
    Skrivele, I.
    Dombi, Z.
    Nemeth, G.
    EUROPEAN PSYCHIATRY, 2020, 63 : S554 - S555
  • [40] A long-term, prospective, observational cohort study of the safety and effectiveness of etanercept for the treatment of patients with paediatric psoriasis in a naturalistic setting
    Gu, Yun
    Brinkley, Emma
    Largent, Joan
    Sobel, Rachel E.
    Colli, Sara
    Thaci, Diamant
    Seyger, Marieke
    Szalai, Zsuzsanna
    Lacour, Jean-Philippe
    Stahle, Mona
    EUROPEAN JOURNAL OF DERMATOLOGY, 2023, 33 (01) : 25 - 33